EP4368183A4 - Pharmazeutische zusammensetzung zur krebsprävention oder -behandlung mit cdk4/6-inhibitor und tricyclischem antidepressivum - Google Patents

Pharmazeutische zusammensetzung zur krebsprävention oder -behandlung mit cdk4/6-inhibitor und tricyclischem antidepressivum

Info

Publication number
EP4368183A4
EP4368183A4 EP22837896.4A EP22837896A EP4368183A4 EP 4368183 A4 EP4368183 A4 EP 4368183A4 EP 22837896 A EP22837896 A EP 22837896A EP 4368183 A4 EP4368183 A4 EP 4368183A4
Authority
EP
European Patent Office
Prior art keywords
inhibitor
pharmaceutical composition
cancer prevention
treatment containing
tricyclic antidepressant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22837896.4A
Other languages
English (en)
French (fr)
Other versions
EP4368183A1 (de
Inventor
Yong Doo Choi
Sung Ho Goh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Center Japan
National Cancer Center Korea
Original Assignee
National Cancer Center Japan
National Cancer Center Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Center Japan, National Cancer Center Korea filed Critical National Cancer Center Japan
Publication of EP4368183A1 publication Critical patent/EP4368183A1/de
Publication of EP4368183A4 publication Critical patent/EP4368183A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP22837896.4A 2021-07-06 2022-06-30 Pharmazeutische zusammensetzung zur krebsprävention oder -behandlung mit cdk4/6-inhibitor und tricyclischem antidepressivum Pending EP4368183A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210088445 2021-07-06
PCT/KR2022/009462 WO2023282544A1 (ko) 2021-07-06 2022-06-30 Cdk4/6 억제제 및 삼환계 항우울제를 포함하는 암의 예방 또는 치료를 위한 약학적 조성물

Publications (2)

Publication Number Publication Date
EP4368183A1 EP4368183A1 (de) 2024-05-15
EP4368183A4 true EP4368183A4 (de) 2025-07-02

Family

ID=84800644

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22837896.4A Pending EP4368183A4 (de) 2021-07-06 2022-06-30 Pharmazeutische zusammensetzung zur krebsprävention oder -behandlung mit cdk4/6-inhibitor und tricyclischem antidepressivum

Country Status (6)

Country Link
US (1) US20240307393A1 (de)
EP (1) EP4368183A4 (de)
JP (1) JP7681791B2 (de)
KR (1) KR102861622B1 (de)
CN (1) CN117597126A (de)
WO (1) WO2023282544A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117982667B (zh) * 2024-04-02 2024-06-21 四川省肿瘤医院 靶向TLR4-MD2/MyD88信号通路的递送系统、其制备方法及其应用
CN118649159A (zh) * 2024-06-12 2024-09-17 深圳技术大学 盐酸多塞平在制备抗肿瘤药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2363394A1 (es) * 2010-01-19 2011-08-02 Universidad De Sevilla Uso de amitriptilina como agente antitumoral para el tratamiento de cáncer de pulmón.
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
US20140271727A1 (en) * 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
JP2018008914A (ja) * 2016-07-15 2018-01-18 国立大学法人金沢大学 抗脳腫瘍剤及び脳腫瘍治療用医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2726074B1 (de) * 2011-07-01 2018-04-04 Novartis AG Kombinationstherapie mit einem cdk4/6-hemmer und einem pi3k-hemmer zur verwendung bei der behandlung von krebs
EP3463453A1 (de) * 2016-05-23 2019-04-10 Eli Lilly and Company Kombination von pembrolizumab und abemaciclib zur behandlung von krebs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2363394A1 (es) * 2010-01-19 2011-08-02 Universidad De Sevilla Uso de amitriptilina como agente antitumoral para el tratamiento de cáncer de pulmón.
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
US20140271727A1 (en) * 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
JP2018008914A (ja) * 2016-07-15 2018-01-18 国立大学法人金沢大学 抗脳腫瘍剤及び脳腫瘍治療用医薬組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARIMOCHI ET AL: "Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 541, no. 1-2, 10 July 2006 (2006-07-10), pages 17 - 23, XP005551466, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2006.04.053 *
LIU MINGHUI ET AL: "Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review)", ONCOLOGY REPORTS, vol. 39, no. 3, 1 January 2018 (2018-01-01), pages 901 - 911, XP055880574, ISSN: 1021-335X, DOI: 10.3892/or.2018.6221 *
PILKINGTON GEOFFREY J ET AL: "The role of tricyclic drugs in selective triggering of mitochondrially-mediated apoptosis in neoplastic glia: a therapeutic option in malignant glioma?", RADIOLOGY AND ONCOLOGY, ASSOCIATION OF RADIOLOGY AND ONCOLOGY, LJUBLJANA, SI, vol. 40, no. 2, 1 January 2006 (2006-01-01), pages 73 - 85, XP009137782, ISSN: 1318-2099 *
PORATTI MELANIA ET AL: "Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 172, 4 April 2019 (2019-04-04), pages 143 - 153, XP085668683, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2019.03.064 *
See also references of WO2023282544A1 *
YUAN SHEAU-YUN ET AL: "Nortriptyline induces mitochondria and death receptor-mediated apoptosis in bladder cancer cells and inhibits bladder tumor growthin vivo", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 761, 15 June 2015 (2015-06-15), pages 309 - 320, XP029254505, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2015.06.007 *

Also Published As

Publication number Publication date
US20240307393A1 (en) 2024-09-19
JP7681791B2 (ja) 2025-05-22
WO2023282544A1 (ko) 2023-01-12
EP4368183A1 (de) 2024-05-15
CN117597126A (zh) 2024-02-23
KR102861622B1 (ko) 2025-09-18
KR20230007945A (ko) 2023-01-13
JP2024524567A (ja) 2024-07-05

Similar Documents

Publication Publication Date Title
EP4473970A4 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren
EP3777888A4 (de) Pharmazeutische zusammensetzung zur behandlung und/oder prävention von krebs
EP4115887A4 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von krebs mit kras-mutation und aktiviertem ron
EP4146198A4 (de) Neue stoffzusammensetzungen und pharmazeutische zusammensetzungen
BR112012010705A2 (pt) composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio
DE60118571D1 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
EP4368183A4 (de) Pharmazeutische zusammensetzung zur krebsprävention oder -behandlung mit cdk4/6-inhibitor und tricyclischem antidepressivum
EP4461735A4 (de) Verbindung zur hemmung und zum abbau von irak4 sowie pharmazeutische zusammensetzung und pharmazeutische anwendung davon
EP4151227A4 (de) Pharmazeutische zusammensetzung zur behandlung von krebs
EP4434531A4 (de) Pharmazeutische zusammensetzung und gesundheitsfunktionelles nahrungsmittel zur krebsprävention oder -behandlung mit gemischtem pflanzlichem medizinextrakt
EP4438048A4 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von t-zell-bedingten erkrankungen
EP4000609A4 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von knochenerkrankungen
EP4215531A4 (de) Verbindung zur prävention und behandlung von lebererkrankungen und pharmazeutische verwendung davon
EP3821886A4 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von krebs mit gossypol, phenformin und antikrebsmittel
EP4159235A4 (de) Pd-1-agonistenhaltige pharmazeutische zusammensetzung zur behandlung oder prävention von th2-vermittelter erkrankung
EP4364740A4 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von krebs
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
EP4467140A4 (de) Pharmazeutische kombination zur behandlung von tumoren und verwendung davon
EP4427755A4 (de) Pharmazeutische zusammensetzung mit salmonella-stamm und immuncheckpoint-inhibitor als wirkstoff zur prävention oder behandlung von krebs
EP4176880A4 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von krebs mit 3-ketoacyl-coa-thiolasehemmer und carnitinacylcarnitinträgerhemmer
EP4230209C0 (de) Pharmazeutische zusammensetzung, pharmazeutische kombination und kombinations-kit zur prävention oder behandlung von chronischer hepatitis b
CO2025006082A2 (es) Compuestos y su uso para el tratamiento de hemoglobinopatías
EP4582087A4 (de) Pharmazeutische zusammensetzung zur behandlung von lymphomen
EP4417197A4 (de) Pharmazeutische zusammensetzung zur behandlung von kastrationsresistentem prostatakrebs mit bruceantin und nanopartikeln
EP4368197A4 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von erkrankungen im zusammenhang mit der reduktion oder dem defekt der tm5u-modifikation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031506000

Ipc: A61K0031135000

A4 Supplementary search report drawn up and despatched

Effective date: 20250528

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20250523BHEP

Ipc: A61K 45/06 20060101ALI20250523BHEP

Ipc: A61K 31/137 20060101ALI20250523BHEP

Ipc: A61K 31/55 20060101ALI20250523BHEP

Ipc: A61K 31/519 20060101ALI20250523BHEP

Ipc: A61K 31/506 20060101ALI20250523BHEP

Ipc: A61K 31/135 20060101AFI20250523BHEP